Lancet: Gabba spray is used for the treatment of chronic pelvic pain.

Globally, 2-24% of women are affected by chronic pelvic pain, and there is no effective treatment.
Gabba spray has good therapeutic effect on some chronic pain.
recently assessed the efficacy and safety of gabal spray for patients with chronic pelvic pain without significant pelvic lesions.
study, conducted in 39 hospitals across the UK, involved women with chronic pelvic pain (with or without pain or difficulty having sex) for at least three months.
age range of 18-50 years old, laparoscopic examination no obvious pelvic pathological lesions.
participants were randomly assigned gaba spray (the dose gradually increased to a maximum dose of 2,700 mg per day) or a placebo for a period of 16 weeks.
of the study was the difference in average pain score (NRS), which assessed the highest pain score and the average pain score, respectively.
306 patients were involved in the study, including 153 in the Gabba spray group and 153 in the placebo group.
13-16 weeks, there was no significant difference in the highest average pain scores between the groups.
NRS pain score was 7.1 in the Gabba spray group and 7.4 in the placebo group.
the Gabba spraying group compared to the baseline, the average change in pain score was -1.4 and that of the placebo group was .2.
average NRS pain score was 4.3 in the Gabba spray group and 4.5 in the placebo group, with average variations of −1.1 and −0.9, respectively, compared to the baseline.
high rates of severe adverse events (7 vs 2%) occurred in the Gabba spray group, with the most common adverse events being dizziness, drowsiness and visual impairment.
study concluded that gabal spray had no significant effect on reducing pain levels in women with chronic pelvic pain.
.